拓扑替康联合顺铂治疗晚期卵巢癌的近期疗效观察  

Clinical research of chemotherapy with topotecan and cisplatin in patients with advanced ovarian cancer

作　　者：万里新[1] 王旸[1] 惠双[1] 

机构地区：[1]南阳市中心医院,河南南阳473009

出　　处：《现代肿瘤医学》2006年第10期1281-1283,共3页Journal of Modern Oncology

摘　　要：目的:观察拓扑替康(TPT)联合顺铂(PDD)治疗晚期卵巢癌的疗效、毒副反应。方法:对45例临床确诊的晚期卵巢癌病人进行化疗,TPT0.75mg/m2,PDD20mg/m2,连用5天为1个疗程,21天为1周期,2个周期结束后评价疗效。结果:45例病人化疗后,总有效率44.44%(20/45),其中初治病人有效率68.75%(11/16),复治病人有效率31.03%(9/29)。化疗后毒副作用主要表现为骨髓抑制,白细胞下降75.56%(34/45),Ⅲ度以上46.67%(21/45);血小板下降44.44%(20/45),Ⅲ度以上24.44%(11/45)。结论:TPT联合PDD治疗晚期卵巢癌,疗效肯定;尤其是对复发病人仍有效,可做为复发卵巢癌的二线或三线化疗。Objective：To observe the therapeutic effect and toxic reaction of salvage chemotherapy with topotecan and cisplatin in patients with advanced ovarian cancer. Methods： Forty five patients with advanced ovarian cancer were treated with chemotherapy, TPT 0.75mg/m^2, PDD 20mg/m^2, continuously for 5 days, twenty one days one cycle. The therapeutic effect was evaluated after two cycles. Results： After chemotherapy of these 45 patients, the overall response rate was 44.44% （20/45） ,among them, the response rate of initial treated patients was 68.75% （ 11/ 19）, that of retreated patints was 31.03% （9/26）. The toxic reactions after chemotherapy were mainly myelosuppression, white blood cells reduced 75.56% （34/45）, above Ⅲ grade was 46.67% （21/45） ;thrombocytopenia reduced 44.44% （ 20/45 ）, above Ⅲ grade 24.44% （ 1 1/45 ）. Conclusion ： The combination of TPT and PDD is effective for advanced ovarian cancer, especially for recurrent patients. It can be used in the patients with recurrent ovarian cancer as a second or third line therapy.

关 键 词：卵巢癌 拓扑替康 顺铂 

分 类 号：R737.31[医药卫生—肿瘤]